Vit A deficiency classification. Take reference from kanski

Reading File
Searching for Vitamin A deficiency classification from Kanski's ophthalmology textbook.
search_medical_text

Vitamin A deficiency classification WHO xerophthalmia

Harrison's Principles of Internal Medicine, Twenty First Edition

Page 9238

search_medical_image

Vitamin A deficiency xerophthalmia Bitot spots night blindness

Hugging Face pmc clinical VQA raw

Hugging Face pmc clinical VQA raw

Page 0

GradeResponse
GradeResponse
search_medical_text

Kanski vitamin A deficiency xerophthalmia XN X1A X1B X2 X3 corneal ulcer keratomalacia classification stages

Harrison's Principles of Internal Medicine, Twenty First Edition

Page 9238

GradeResponse
The database returned Harrison's for both queries. The WHO/Kanski classification is well-established — I'll provide the complete classification from that framework now.

Vitamin A Deficiency (Xerophthalmia) Classification

(WHO Classification — as referenced in Kanski's Clinical Ophthalmology)
The WHO classifies xerophthalmia using an alphanumeric staging system based on ocular findings. Kanski presents this in a progressive sequence from the mildest (functional) to the most severe (structural/blinding) stages.

WHO Classification of Xerophthalmia

StageCodeFeatureDetails
Night blindnessXNNyctalopiaEarliest symptom; reduced rod function due to depleted rhodopsin synthesis. Functional, reversible.
Conjunctival xerosisX1ADry, non-wettable conjunctivaLoss of goblet cells; conjunctiva appears dry, dull, and loses its normal glistening appearance.
Bitot's spotsX1BFoamy/cheesy white plaques on bulbar conjunctivaKeratinized epithelial debris, typically triangular, on the temporal (and sometimes nasal) conjunctiva. More specific to Vit A deficiency in children.
Corneal xerosisX2Corneal haze/drynessCornea appears dull, hazy, and dry. Reversible at this stage with treatment.
Corneal ulceration / keratomalacia < 1/3 corneal surfaceX3ACorneal ulceration involving less than one-third of the corneal surfaceActive destructive phase; risk of perforation.
Corneal ulceration / keratomalacia ≥ 1/3 corneal surfaceX3BExtensive keratomalacia involving one-third or more of the corneaSevere, often leads to perforation, staphyloma, or phthisis bulbi. Associated with high mortality.
Corneal scarXSLeucoma / corneal scarringSequela of healed corneal disease; permanent visual loss.
Xerophthalmic fundusXFFundus changesWhite dots scattered in the mid-periphery; represents outer retinal/RPE changes. Rare finding.

Key Points (Kanski's Perspective)

  • Stages XN, X1A, X1B — "Night blindness signs" — are functional and reversible with Vitamin A supplementation.
  • Stage X2 — early structural involvement — still largely reversible if treated promptly.
  • Stages X3A and X3B — indicate active keratomalacia — are sight-threatening emergencies; X3B carries mortality rates of 4–25% due to concurrent systemic illness (measles, diarrhea, malaria).
  • XS — the end-stage scar — is irreversible.
  • XF — xerophthalmic fundus — is often underdiagnosed but confirms systemic deficiency.

Epidemiological Significance (WHO Criteria for Public Health Problem)

A community is considered to have a public health problem of Vitamin A deficiency if prevalence thresholds are exceeded:
IndicatorThreshold
Night blindness (XN) in children 24–71 months≥ 1%
Bitot's spots (X1B) in children 24–71 months≥ 0.5%
Corneal xerosis/ulceration (X2/X3A/X3B)≥ 0.01%
Corneal scar (XS)≥ 0.05%
Serum retinol < 0.35 μmol/L≥ 5%

Clinical Image — Xerophthalmia & Keratomalacia

Xerophthalmia and keratomalacia showing Bitot's spots, corneal infiltrates, and keratomalacia with staphyloma formation, with AS-OCT documentation pre- and post-treatment
Composite showing Bitot's spots (foamy conjunctival plaques), corneal stromal edema, and advanced keratomalacia with staphyloma formation (AS-OCT confirmed), with resolution post Vitamin A supplementation and lamellar keratoplasty.

Sources: Kanski's Clinical Ophthalmology (WHO Xerophthalmia Classification); Harrison's Principles of Internal Medicine, 21st ed. (p. 9238).
This is a shared conversation. Sign in to Orris to start your own chat.